Loss of scalp and body hair involving microscopically inflammatory patchy areas.
Absence of hair from areas where it is normally present.
The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
A tube-like invagination of the EPIDERMIS from which the hair shaft develops and into which SEBACEOUS GLANDS open. The hair follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. (Stedman, 26th ed) Follicles of very long hairs extend into the subcutaneous layer of tissue under the SKIN.
A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371)
A noninvasive technique that enables direct microscopic examination of the surface and architecture of the SKIN.
A filament-like structure consisting of a shaft which projects to the surface of the SKIN from a root which is softer than the shaft and lodges in the cavity of a HAIR FOLLICLE. It is found on most surfaces of the body.
Inbred C3H mice are a strain of laboratory mice that have been selectively bred to maintain a high degree of genetic uniformity and share specific genetic characteristics, including susceptibility to certain diseases, which makes them valuable for biomedical research purposes.
Compulsion to pull out one's hair.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
An alkylamino-alcohol complex of inosine used in the treatment of a variety of viral infections. Unlike other antiviral agents, it acts by modifying or stimulating cell-mediated immune processes rather than acting on the virus directly.
Cyclobutanes are saturated hydrocarbons consisting of a four-carbon ring with only carbon-carbon sigma bonds, making up the smallest cycloalkane ring that can adopt a puckered conformation to alleviate angle strain. (25 words)
A topical glucocorticoid used in the treatment of ECZEMA.
Curved rows of HAIR located on the upper edges of the eye sockets.
A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.
An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.
A by-product of the destructive distillation of coal used as a topical antieczematic. It is an antipruritic and keratoplastic agent used also in the treatment of psoriasis and other skin conditions. Occupational exposure to soots, tars, and certain mineral oils is known to be carcinogenic according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985) (Merck Index, 11th ed).
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
**I must clarify that there is no recognized or established medical term or definition for 'Texas.' However, if you're asking for a possible humorous play on words using the term 'Texas' in a medical context, here it is:**
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.

Contribution of interleukin 1beta and KM loci to alopecia areata. (1/140)

Alopecia areata is a common skin disease in which proinflammatory cytokines such as IL-1beta may play a pathogenic role. In this study, we examined the distribution of genotypes of an IL-1beta single base change polymorphism at position +3953 in patients with alopecia areata. The distribution of immunoglobulin kappa light chain (KM) genotypes was similarly examined. The data obtained showed that the IL-1beta and KM loci act cooperatively to significantly increase susceptibility to alopecia areata.  (+info)

Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice. (2/140)

A type of hair loss closely resembling human alopecia areata has been described in C3H/HeJ mice. In order to test the assumed analogy with human alopecia areata, we investigated the efficacy of treatment with the contact allergen squaric acid dibutylester. In 12 C3H/HeJ mice with alopecia areata an allergic contact dermatitis was induced and elicited weekly on one side of the back by topical applications of squaric acid dibutylester. Overt hair regrowth was observed only on the treated side of the back in nine of 12 mice. Histopathologic examination revealed a change in the distribution of the inflammatory infiltrate from a dense perifollicular lymphocytic infiltrate around the mid and lower regions of hair follicles in untreated skin to a uniform presence in the upper dermis in treated skin. Immunohistomorphometric studies revealed that treatment with squaric acid dibutylester increased the CD4+/CD8+ ratio from approximately 1:2 in untreated alopecia areata to 1:1 in treated alopecia areata. Additional immunohistochemical investigations showed an aberrant expression of major histocompatibility complex class I, major histocompatibility complex class II and intercellular adhesion molecule 1 on keratinocytes of the mid and lower parts of hair follicles in untreated alopecia areata. In successfully treated skin ectopic major histocompatibility complex class I and II expression was clearly reduced, whereas intercellular adhesion molecule 1 expression showed only minor changes. In conclusion, alopecia areata-like hair loss in C3H/HeJ mice responded to treatment with the contact sensitizer squaric acid dibutylester analogous to human alopecia areata. Moreover, successful treatment changes the aberrant expression of major histocompatibility complex class I and II in a way similar to that observed in human alopecia areata. These observations support the concept that alopecia areata-like hair loss in C3H/HeJ mice can be utilized as an appropriate model for the study of human alopecia areata.  (+info)

Role of cytotoxic T cells in chronic alopecia areata. (3/140)

Cytokines play a role in alopecia areata. We used immunohistochemical and in situ hybridization studies to demonstrate the persistence of pro-inflammatory as well as apoptotic mechanisms in skin biopsies from patients with chronic alopecia areata. In situ hybridization allows the visualization of the distribution of immunocompetent cells in vivo. We studied skin biopsies from 11 untreated alopecia areata patients and two normal controls. In situ hybridization was performed on frozen sections using 35S-radio-labeled riboprobes, specific for IL-1beta, IL-2, IL-6, INFgamma, and granzyme B mRNA. Immunohistochemistry was carried out using an anti-IL-1beta monoclonal antibody, and a monoclonal antibody directed against the human Fas protein. We demonstrated the presence of cells labeled with IL-1beta, IL-6, INFgamma, and granzyme B antisense probes. Similarly, cells labeled with anti-IL-1beta were found in 10 of 11 cases. The labeled cells were located in the mononuclear peri- and intrafollicular infiltrate. Cells expressing granzyme B were found in close contact with the follicle. Fas positivity was demonstrated in four of four cases at the level of the cytoplasmic membrane of the hair follicle keratinocytes. These results, based on visualizing the labeled cells, demonstrate that pro-inflammatory cytokines are produced by the mononuclear cell infiltrate in close contact with follicles in alopecia areata. Furthermore, they demonstrate for the first time that apoptotic mechanisms involving granzyme B and Fas-Fas ligand pathways may play a major role in the persistence of chronic alopecia areata.  (+info)

Heavy metal poisoning in glass worker characterised by severe. (4/140)

The paper presents the clinical description of the masticatory organ and biochemical assessment of dental tissue in a patient employed in a glassworks for 20 years. During 12 years the patient has suffered baldness ("Alopecia areata") and atypical extensive and non-healing cutaneous lesions. Dental examination revealed changes typical of chronic poisoning by cadmium and bismuth compounds.  (+info)

Practical management of hair loss. (5/140)

OBJECTIVE: To describe an organized diagnostic approach for both nonscarring and scarring alopecias to help family physicians establish an accurate in-office diagnosis. To explain when ancillary laboratory workup is necessary to confirm the diagnosis. QUALITY OF EVIDENCE: Current diagnostic and therapeutic interventions for hair loss are based on randomized controlled studies, uncontrolled studies, and case series. MEDLINE was searched from January 1966 to December 1998 with the MeSH words alopecia, hair, and alopecia areata. Articles were selected on the basis of experimental design, with priority given to the most current large multicentre controlled studies. Overall global evidence for therapeutic intervention for hair loss is quite strong. MAIN MESSAGE: The most common forms of nonscarring alopecias are androgenic alopecia, telogen effluvium, and alopecia areata. Other disorders include trichotillomania, traction alopecia, tinea capitis, and hair shaft abnormalities. Scarring alopecia is caused by trauma, infections, discoid lupus erythematosus, or lichen planus. Key to establishing an accurate diagnosis is a detailed history, including medication use, systemic illnesses, endocrine dysfunction, hair-care practices, and family history. All hair-bearing sites should be examined. A 4-mm punch biopsy of the scalp is useful, particularly to diagnose scarring alopecias. Once a diagnosis has been established, specific therapy can be initiated. CONCLUSIONS: Diagnosis and management of hair loss is an interesting challenge for family physicians. An organized approach to recognizing characteristic differential features of hair loss disorders is key to diagnosis and management.  (+info)

Treatment with an anti-CD44v10-specific antibody inhibits the onset of alopecia areata in C3H/HeJ mice. (6/140)

A murine CD44v10-neutralizing antibody has been reported to impair delayed-type hypersensitivity reactions. Because alopecia areata is characterized by a delayed-type hypersensitivity-like T cell mediated immune response, we addressed the question whether an anti-CD44v10-antibody influences the onset of alopecia areata. Therefore, we used the C3H/HeJ mouse model with the induction of alopecia areata in unaffected mice by the grafting of lesional alopecia areata mouse skin. Six grafted mice were injected (intraperitoneally) with anti-CD44v10, six grafted mice with anti-CD44standard, and six with phosphate-buffered saline only. After 11 wk phosphate-buffered saline injected animals on average had developed alopecia areata on 36.8% of their body. The onset of hair loss was slightly delayed and its extent reduced to 17.2% of their body in anti-CD44standard-treated mice. By contrast, five of six anti-CD44v10-treated mice did not show any hair loss and one mouse developed alopecia areata on only 1% of the body. Immunohistochemical examination revealed a marked reduction of perifollicular CD8+ lymphocytes and, to a lesser degree, CD4+ cells as well as a decreased expression of major histocompatibility complex class I on hair follicle epithelium in anti-CD44v10-treated mice as compared with phosphate-buffered saline or anti-CD44 standard-treated mice. Our data show that anti-CD44v10 is able to inhibit the onset of alopecia areata in C3H/HeJ mice. This might be accomplished by an anti-CD44v10-triggered impairment of immune cell homing (e.g., CD8+ T cells), resulting in a decrease of their number in target tissues.  (+info)

Interleukin-1 receptor antagonist allele 2 and familial alopecia areata. (7/140)

Alopecia areata affects 1%-2% of the population and is hypothesized to be an autoimmune, organ specific T-cell mediated reaction directed against the human hair follicle. It is characterized by loss of hair in patches (alopecia areata) with progression in some individuals to total loss of scalp hair (alopecia totalis) or to loss of all scalp and body hair (alopecia universalis). The interleukin-1 receptor antagonist (IL-1RN) gene was found to be associated with more severe clinical outcome in several chronic inflammatory diseases, including alopecia areata. The IL-1RN*2 allele was found to be associated with alopecia areata severity in a British case-control study. In this paper, we analyzed alopecia areata probands in a family-based sample (n = 131 parent-offspring trios) to study the association between alleles of the IL-1RN and various phenotypes of alopecia areata. In considering all patients with any form of alopecia areata, no association was found with IL-1RN. IL-1RN*2 allele was not associated with alopecia totalis and alopecia universalis. A borderline association was observed between IL-1RN and patchy alopecia areata but it was not statistically significant (p =0.06). We also observed an association between IL1-RN*1 allele and patchy alopecia areata (p =0.045).  (+info)

Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. (8/140)

Alopecia areata is a tissue restricted autoimmune condition affecting the hair follicle, resulting in hair loss. The goal of this study was to test the hypothesis that the autoantigen of alopecia areata is melanocyte associated. Potential autoantigens were tested in the human scalp explant/Prkd(scid) CB-17 mouse transfer system. Scalp T cells from lesional (bald) alopecia areata scalp were cultured with antigen-presenting cells, and antigen, along with interleukin-2. The T cells were then injected into autologous lesional scalp grafts on SCID mice, and hair regrowth was measured. Hair follicle homogenate was used as an autoantigen control. T cells cultured with melanoma homogenate induced statistically significant reduction in hair growth (p <0.01 by ANOVA). HLA-A2-restricted melanocyte peptide epitopes were then tested with lesional scalp T cells from HLA-A2-positive alopecia areata patients. Melanocyte-peptide-activated T cells significantly reduced the number of hairs regrowing in two experiments with six patients (p <0.001 by ANOVA). Injected scalp grafts showed histologic and immunochemical changes of alopecia areata. The most consistent peptide autoantigens were the Gp100-derived G9-209 and G9-280 peptides, as well as MART-1 (27-35). Melanocyte peptide epitopes can function as autoantigens for alopecia areata. Multiple peptides were recognized, suggesting epitope spreading.  (+info)

Alopecia Areata is a medical condition characterized by the sudden loss of hair in round or oval patches on the scalp or other parts of the body. It is an autoimmune disorder, which means that the immune system mistakenly attacks the hair follicles, leading to hair loss. The condition can affect both adults and children, and it can cause significant emotional distress and impact a person's quality of life. In some cases, the hair may grow back on its own, while in others, treatment may be necessary to promote hair regrowth.

Alopecia is a medical term that refers to the loss of hair or baldness. It can occur in various parts of the body, but it's most commonly used to describe hair loss from the scalp. Alopecia can have several causes, including genetics, hormonal changes, medical conditions, and aging.

There are different types of alopecia, such as:

* Alopecia Areata: It is a condition that causes round patches of hair loss on the scalp or other parts of the body. The immune system attacks the hair follicles, causing the hair to fall out.
* Androgenetic Alopecia: Also known as male pattern baldness or female pattern baldness, it's a genetic condition that causes gradual hair thinning and eventual hair loss, typically following a specific pattern.
* Telogen Effluvium: It is a temporary hair loss condition caused by stress, medication, pregnancy, or other factors that can cause the hair follicles to enter a resting phase, leading to shedding and thinning of the hair.

The treatment for alopecia depends on the underlying cause. In some cases, such as with telogen effluvium, hair growth may resume without any treatment. However, other forms of alopecia may require medical intervention, including topical treatments, oral medications, or even hair transplant surgery in severe cases.

The scalp is the anatomical region located at the upper part of the human head, covering the skull except for the face and the ears. It is made up of several layers: the skin, the connective tissue, the galea aponeurotica (a strong, flat, tendinous sheet), loose areolar tissue, and the periosteum (the highly vascularized innermost layer that attaches directly to the skull bones). The scalp has a rich blood supply and is home to numerous sensory receptors, including those for touch, pain, and temperature. It also contains hair follicles, sebaceous glands, and sweat glands.

A hair follicle is a part of the human skin from which hair grows. It is a complex organ that consists of several layers, including an outer root sheath, inner root sheath, and matrix. The hair follicle is located in the dermis, the second layer of the skin, and is surrounded by sebaceous glands and erector pili muscles.

The hair growth cycle includes three phases: anagen (growth phase), catagen (transitional phase), and telogen (resting phase). During the anagen phase, cells in the matrix divide rapidly to produce new hair fibers that grow out of the follicle. The hair fiber is made up of a protein called keratin, which also makes up the outer layers of the skin and nails.

Hair follicles are important for various biological functions, including thermoregulation, sensory perception, and social communication. They also play a role in wound healing and can serve as a source of stem cells that can differentiate into other cell types.

Minoxidil is a medication that is primarily used to treat hair loss. It is a vasodilator, which means it widens blood vessels and improves blood flow. When applied to the scalp, it helps to stimulate hair growth and slows down hair loss. It is available in topical form as a solution or foam, and is usually applied once or twice a day. Minoxidil is not intended for use in children, and women who are pregnant or breastfeeding should consult with their doctor before using it.

It's important to note that minoxidil does not work for everyone, and it may take several months of regular use before any new hair growth is seen. Additionally, if the medication is discontinued, any hair gained during treatment will likely be lost over time. Common side effects of minoxidil include scalp irritation, unwanted hair growth on other parts of the body, and changes in the color or texture of existing hair. It's important to follow the instructions provided by a healthcare professional when using minoxidil.

Dermoscopy, also known as dermatoscopy or epiluminescence microscopy, is a non-invasive diagnostic technique used in dermatology to evaluate skin lesions, such as moles and pigmented skin tumors. This method involves the use of a handheld device called a dermoscope, which consists of a magnifying lens, a light source, and a transparent plate or immersion fluid that allows for better visualization of the skin's surface structures.

Dermoscopy enables dermatologists to examine the pigmented patterns, vascular structures, and other morphological features hidden beneath the skin's surface that are not visible to the naked eye. By observing these details, dermatologists can improve their ability to differentiate between benign and malignant lesions, leading to more accurate diagnoses and appropriate treatment decisions.

The primary uses of dermoscopy include:

1. Early detection and diagnosis of melanoma and other skin cancers, such as basal cell carcinoma and squamous cell carcinoma.
2. Monitoring the evolution of suspicious moles or lesions over time.
3. Assisting in the identification of various benign skin growths, like seborrheic keratoses, dermatofibromas, and nevi (moles).
4. Improving the diagnostic accuracy for infectious skin conditions, inflammatory processes, and other dermatological disorders.

Overall, dermoscopy is a valuable tool in the field of dermatology that enhances the clinician's ability to diagnose and manage various skin conditions accurately and effectively.

Medically, hair is defined as a threadlike structure that grows from the follicles found in the skin of mammals. It is primarily made up of a protein called keratin and consists of three parts: the medulla (the innermost part or core), the cortex (middle layer containing keratin filaments) and the cuticle (outer layer of overlapping scales).

Hair growth occurs in cycles, with each cycle consisting of a growth phase (anagen), a transitional phase (catagen), and a resting phase (telogen). The length of hair is determined by the duration of the anagen phase.

While hair plays a crucial role in protecting the skin from external factors like UV radiation, temperature changes, and physical damage, it also serves as an essential aspect of human aesthetics and identity.

'C3H' is the name of an inbred strain of laboratory mice that was developed at the Jackson Laboratory in Bar Harbor, Maine. The mice are characterized by their uniform genetic background and have been widely used in biomedical research for many decades.

The C3H strain is particularly notable for its susceptibility to certain types of cancer, including mammary tumors and lymphomas. It also has a high incidence of age-related macular degeneration and other eye diseases. The strain is often used in studies of immunology, genetics, and carcinogenesis.

Like all inbred strains, the C3H mice are the result of many generations of brother-sister matings, which leads to a high degree of genetic uniformity within the strain. This makes them useful for studying the effects of specific genes or environmental factors on disease susceptibility and other traits. However, it also means that they may not always be representative of the genetic diversity found in outbred populations, including humans.

Trichotillomania is defined as an irresistible urge or impulse to pull out one's hair from the scalp, eyebrows, eyelashes, or other areas of the body, resulting in noticeable hair loss. It is a mental disorder that falls under the category of obsessive-compulsive and related disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

People with trichotillomania may experience increasing tension or anxiety before pulling their hair, and they often feel relief or pleasure after doing so. The behavior can occur during periods of stress or as a way to cope with negative emotions, but it can also happen without the individual being fully aware of it.

In addition to hair loss, trichotillomania can cause significant distress and impairment in social, occupational, or other areas of functioning. Treatment typically involves cognitive-behavioral therapy (CBT) and medication, such as selective serotonin reuptake inhibitors (SSRIs).

Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from foreign invaders like bacteria and viruses, mistakenly attacks the body's own cells and tissues. This results in inflammation and damage to various organs and tissues in the body.

In autoimmune diseases, the body produces autoantibodies that target its own proteins or cell receptors, leading to their destruction or malfunction. The exact cause of autoimmune diseases is not fully understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

There are over 80 different types of autoimmune diseases, including rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, psoriasis, and inflammatory bowel disease. Symptoms can vary widely depending on the specific autoimmune disease and the organs or tissues affected. Treatment typically involves managing symptoms and suppressing the immune system to prevent further damage.

Inosine pranobex is not a medication with a widely accepted or universally recognized medical definition, as it is known by several different names and its exact mechanism of action is not completely understood. However, it is commonly referred to in medical literature as an immunomodulator, which is a substance that can modify the immune system's response to various stimuli.

Inosine pranobex is also known as Isoprinosine, and its active ingredients are inosine and p-acetamidobenzoate. It has been used off-label in some countries for the treatment of viral infections, including herpes simplex virus and influenza, although its efficacy for these indications is not well established.

Inosine pranobex is thought to work by stimulating the immune system's response to viral infections, enhancing the activity of natural killer cells and increasing the production of interferon, a protein that helps protect cells from viral infection. However, more research is needed to fully understand its mechanisms of action and potential therapeutic uses.

Cyclobutanes are a class of organic compounds that contain a four-membered carbon ring. The carbons in this ring are bonded to each other in a cyclic arrangement, forming a square-like structure. These compounds can be found naturally or synthesized in the laboratory and play important roles in various chemical reactions and biological processes.

Cyclobutanes are relatively uncommon in nature due to the strain associated with having four carbons in a small ring. This strain makes the molecules more reactive, which can lead to interesting chemical properties. For example, cyclobutanes can undergo ring-opening reactions when exposed to heat or light, leading to the formation of new chemical bonds and the release of energy.

In biology, cyclobutane rings are found in certain types of DNA damage, such as those caused by ultraviolet (UV) radiation. These damages can lead to mutations and may contribute to the development of skin cancer. However, cells have mechanisms for repairing this type of DNA damage, helping to prevent these negative outcomes.

Overall, while cyclobutanes are relatively simple molecules, they have important implications in chemistry and biology, making them a fascinating area of study.

Fluocinonide is a topical corticosteroid medication that is used to reduce inflammation and relieve itching, redness, and swelling associated with various skin conditions. It works by suppressing the immune system's response to irritation and reducing the production of inflammatory chemicals in the body. Fluocinonide is a potent steroid and is usually prescribed for short-term use only, as long-term use can lead to thinning of the skin, increased vulnerability to infection, and other side effects. It is available in various forms, including creams, ointments, and solutions, and is typically applied directly to the affected area of the skin one to three times a day.

The eyebrows are a set of hairs that grow above the eyes on the forehead. They are an important feature of human facial anatomy, and play several roles in non-verbal communication and self-expression. Eyebrows help to prevent sweat and other moisture from dripping into the eyes, and also serve as a protective barrier against dirt, dust, and other foreign particles that might otherwise irritate or damage the eyes.

In addition, eyebrows play an important role in human social interaction and communication. They can convey a range of emotions and facial expressions, such as surprise, anger, fear, happiness, and sadness. Eyebrows can also help to frame the eyes and enhance their appearance, making them an important aspect of personal grooming and beauty.

The eyebrows are made up of several components, including hair follicles, sebaceous glands, and muscles that control their movement. The hairs themselves are composed of a protein called keratin, which also makes up the hair on the head, as well as nails and skin. The color and thickness of eyebrow hair can vary widely from person to person, and may be influenced by factors such as age, genetics, and hormonal changes.

In medical terms, changes in the appearance or condition of the eyebrows can sometimes be a sign of underlying health issues. For example, thinning or loss of eyebrows can be associated with conditions such as alopecia, thyroid disorders, or nutritional deficiencies. Changes in eyebrow shape or position can also be a symptom of certain neurological conditions, such as Bell's palsy or stroke. As such, any significant changes in the appearance or condition of the eyebrows should be evaluated by a healthcare professional to rule out any underlying medical causes.

Clobetasol is a topical corticosteroid medication that is used to reduce inflammation and relieve itching, redness, and swelling associated with various skin conditions. It works by suppressing the immune system's response to reduce inflammation. Clobetasol is available in several forms, including creams, ointments, emulsions, and foams, and is usually applied to the affected area once or twice a day.

It is important to use clobetasol only as directed by a healthcare provider, as prolonged or excessive use can lead to thinning of the skin, increased susceptibility to infections, and other side effects. Additionally, it should not be used on large areas of the body or for extended periods without medical supervision.

Anthralin is a medication that is used to treat chronic plaque psoriasis. It is a synthetic form of a substance found in the bark of the araroba tree, which has been used traditionally in folk medicine to treat skin conditions. Anthralin works by slowing down the growth of skin cells, reducing inflammation, and helping to flake off scales.

Anthralin is available in various forms, including creams, ointments, and pastes, and is usually applied directly to the affected areas of the skin for a short period of time, typically ranging from 10 to 30 minutes, once or twice a day. It may take several weeks of regular use to see improvement in symptoms.

Anthralin can cause skin irritation, so it's important to follow your healthcare provider's instructions carefully when using this medication. You should also avoid applying anthralin to healthy skin and wash your hands thoroughly after each application to prevent accidentally transferring the medication to other parts of your body.

Coal tar is a thick, dark liquid that is a byproduct of coal manufacturing processes, specifically the distillation of coal at high temperatures. It is a complex mixture of hundreds of different compounds, including polycyclic aromatic hydrocarbons (PAHs), which are known to be carcinogenic.

In medical terms, coal tar has been used topically for various skin conditions such as psoriasis, eczema, and seborrheic dermatitis due to its anti-inflammatory and keratolytic properties. Coal tar can help reduce scaling, itching, and inflammation of the skin. However, its use is limited due to potential side effects such as skin irritation, increased sun sensitivity, and potential risk of cancer with long-term use. Coal tar products should be used under the guidance of a healthcare provider and according to the instructions on the label.

Phase I clinical trials are the first stage of testing a new medical treatment or intervention in human subjects. The primary goal of a Phase I trial is to evaluate the safety and tolerability of the experimental treatment, as well as to determine an appropriate dosage range. These studies typically involve a small number of healthy volunteers or patients with the condition of interest, and are designed to assess the pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the drug) and pharmacodynamics (the biological effects of the drug on the body) of the experimental treatment. Phase I trials may also provide initial evidence of efficacy, but this is not their primary objective. Overall, the data from Phase I trials help researchers determine whether it is safe to proceed to larger-scale testing in Phase II clinical trials.

I'm not aware of any medical definition for the term "Texas." It is primarily used as the name of a state in the United States, located in the southern region. If you're referring to a specific medical term or concept that I might not be aware of, please provide more context or clarify your question.

If you meant to ask for an explanation of a medical condition named 'Texas', it is likely a typo or a misunderstanding, as there is no widely recognized medical condition associated with the name 'Texas'.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

A registry in the context of medicine is a collection or database of standardized information about individuals who share a certain condition or attribute, such as a disease, treatment, exposure, or demographic group. These registries are used for various purposes, including:

* Monitoring and tracking the natural history of diseases and conditions
* Evaluating the safety and effectiveness of medical treatments and interventions
* Conducting research and generating hypotheses for further study
* Providing information to patients, clinicians, and researchers
* Informing public health policy and decision-making

Registries can be established for a wide range of purposes, including disease-specific registries (such as cancer or diabetes registries), procedure-specific registries (such as joint replacement or cardiac surgery registries), and population-based registries (such as birth defects or cancer registries). Data collected in registries may include demographic information, clinical data, laboratory results, treatment details, and outcomes.

Registries can be maintained by a variety of organizations, including hospitals, clinics, academic medical centers, professional societies, government agencies, and industry. Participation in registries is often voluntary, although some registries may require informed consent from participants. Data collected in registries are typically de-identified to protect the privacy of individuals.

"Areata" is derived from the Latin word, "area," meaning a vacant space or patch. Alopecia areata and alopecia barbae have been ... Alopecia areata monolocularis describes baldness in only one spot. It may occur anywhere on the head. Alopecia areata ... Occasionally, in inactive alopecia areata, no inflammatory infiltrates are found.[citation needed] Commonly, alopecia areata ... If all body hair, including pubic hair, is lost, the diagnosis then becomes alopecia areata universalis. Alopecia areata ...
Khan Mohammad Beigi P (2018). "Trichotillomania (Hair Pulling Disorder)". Alopecia Areata. pp. 63-66. doi:10.1007/978-3-319- ... The differential diagnosis will include evaluation for alopecia areata, iron deficiency, hypothyroidism, tinea capitis, ... Feather-plucking Noncicatricial alopecia Psychogenic alopecia, a form of baldness that is caused by excessive grooming in cats ... traction alopecia, alopecia mucinosa, thallium poisoning, and loose anagen syndrome. In trichotillomania, a hair pull test is ...
Tuttle was diagnosed with alopecia areata when she was three years old, which quickly progressed to alopecia universalis, ... "Alopecia Areata". Molly Tuttle. "Molly Tuttle Chart History > Independent Albums". Billboard. Archived from the original on ...
Alopecia areata has been studied on mice in laboratories. In horses, human contact with the horse and the rubbing of the saddle ... Levy, Janey (31 August 2006). Alopecia Areata. The Rosen Publishing Group. p. 46. ISBN 978-1-4042-0693-9. Retrieved 31 October ... "Equine alopecia areata: a retrospective clinical descriptive study at the University of California, Davis (1980-2011)". ... "Psychogenic alopecia in rhesus macaques presenting as focally extensive alopecia of the distal limb". Comparative Medicine. 61 ...
Alopecia areata Alopecia totalis "Alopecia universalis , Disease , Overview , Genetic and Rare Diseases Information Center ( ... Alopecia universalis (AU), also known as alopecia areata universalis, is a medical condition involving the loss of all body ... Khan Mohammad Beigi, Pooya (2018), Khan Mohammad Beigi, Pooya (ed.), "Alopecia Totalis/Universalis", Alopecia Areata: A ... It is the most severe form of alopecia areata. People with the disease are usually healthy and have no other symptoms and a ...
Khan P, Beigi M (2018). Alopecia Areata. doi:10.1007/978-3-319-72134-7. ISBN 978-3-319-72133-0. S2CID 46954629. Kim EJ, Collard ... Diffuse alopecia areata (Diffuse AA) occurs more commonly in people with rheumatoid arthritis. RA is also seen more often in ...
Androgenetic alopecia, Scalp psoriasis and Alopecia areata. male alopecia Alopecia scale Lupus erythematosus Hidradenitis ... Gilhar, Amos; Etzioni, Amos; Paus, Ralf (2012-04-19). "Alopecia areata". The New England Journal of Medicine. 366 (16): 1515- ... "Whole exome sequencing in Alopecia Areata identifies rare variants in KRT82". Nat Commun. 13 (1): 800. doi:10.1038/s41467-022- ... Well known diseases of the hair follicle include alopecia or hair loss, hirsutism or excess hair growth and lupus erythematosus ...
Female androgenetic alopecia, telogen effluvium and alopecia areata - part II". Anais Brasileiros de Dermatologia. 87 (6): 884- ... Alkhalifah, A. (2012). "Alopecia Areata Update". Dermatologic Clinics. 31 (1): 93-108. doi:10.1016/j.det.2012.08.010. PMID ... ISBN 0-7216-2921-0. Khan Mohammad Beigi, Pooya (2018). "Introduction". In Khan Mohammad Beigi, Pooya (ed.). Alopecia Areata: A ... Anagen effluvium Noncicatricial alopecia Marks, James G; Miller, Jeffery (2006). Lookingbill and Marks' Principles of ...
Dibutyl squarate is used for the treatment of warts and for alopecia areata . Diethyl squarate has been used as an intermediate ... Yoshimasu, Takashi; Furukawa, Fukumi (2016). "Modified immunotherapy for alopecia areata". Autoimmunity Reviews. 15 (7): 664- ...
Medically, it is used for the treatment of warts and for treating alopecia areata or alopecia totalis (autoimmune hair loss) ... Yoshimasu, Takashi; Furukawa, Fukumi (2016). "Modified immunotherapy for alopecia areata". Autoimmunity Reviews. 15 (7): 664- ...
There is some tentative evidence that anthralin might be useful for alopecia areata. It temporarily stains the skin a yellowy- ... Shapiro J (December 2013). "Current treatment of alopecia areata". The Journal of Investigative Dermatology. Symposium ...
Lebwohl, Mark (January 1997). "New treatments for alopecia areata". The Lancet. 349 (9047): 222-223. doi:10.1016/S0140-6736(05) ... single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata". ...
... is a topically administered experimental drug intended for treating alopecia areata and alopecia totalis. Topical immunotherapy ... A study of 41 alopecia areata patients showed significant hair regrowth in 40% at 6 months, being sustained in two thirds of ... Bulock KG, Cardia JP, Pavco PA, Levis WR (November 2015). "Diphencyprone Treatment of Alopecia Areata: Postulated Mechanism of ... Benzophenone Cyclopropenone Singh G, Lavanya M (January 2010). "Topical immunotherapy in alopecia areata". International ...
ISBN 978-1-4160-2999-1. Starr, JC; Taneja, N; Brasher, GW (2010). "Relapsing polychondritis following alopecia areata". Case ...
Willemsen, R.; Vanderlinden, J.; Deconinck, A.; Roseeuw, D. (2006). "Hypnotherapeutic management of alopecia areata". Journal ... warts and alopecia areata. Philip D. Shenefelt, a research dermatologist at the University of South Florida School of Medicine ...
American Academy of Dermatology, "Alopecia Areata". Archived from the original on 2010-07-06. Retrieved 2010-07-16. Erjavec SO ... "Whole exome sequencing in Alopecia Areata identifies rare variants in KRT82". Nat Commun. 13 (1): 800. Bibcode:2022NatCo..13.. ... www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/alopecia-areata/index.html Archived 2011-11- ...
Rakowska, A; Slowinska, M; Kowalska-Oledzka, E; Olszewska, M; Czuwara, J; Rudnicka, L (2009). "Alopecia areata incognita: true ... "The role of scalp dermoscopy in the diagnosis of alopecia areata incognita". Journal of the American Academy of Dermatology. 59 ... A new hair disorder described by Antonella Tosti is often referred to as "Tosti Alopecia". Antonella Tosti is author or co- ... Tosti, A; Piraccini, BM; Iorizzo, M; Misciali, C (2005). "Frontal fibrosing alopecia in postmenopausal women". Journal of the ...
... at the National Alopecia Areata Foundation's Teens Conference Camp and has been a spokesperson for the Children's Alopecia ... "The life significance of losing my hair at age 12 from alopecia areata has made me a very strong, determined person." She has ... Published by the National Alopecia Areata Foundation. Retrieved October 29, 2008. http://childrensalopeciaproject.blogspot.com/ ...
"The Genetic Basis of Alopecia Areata: HLA Associations with Patchy Alopecia Areata Versus Alopecia Totalis and Alopecia ... Alopecia areata Alopecia universalis Colombe, Beth W.; Lou, Calvin D.; Price, Vera H. (December 1999). " ... Alopecia totalis is the loss of all hair on the head and face. Its causes are unclear, but believed to be autoimmune. Research ... Scalp cooling has specifically been used to prevent alopecia in docetaxel chemotherapy, although it has been found prophylactic ...
Alopecia areata monolocularis) to every hair on the entire body (Alopecia areata universalis). Although thought to be caused by ... Alopecia areata may be treated by steroid injections in the affected area, but these need to be frequently repeated to be ... Alopecia areata (mild - medium level) usually shows in unusual hair loss areas, e.g., eyebrows, backside of the head or above ... Alopecia areata is an autoimmune disorder also known as "spot baldness" that can result in hair loss ranging from just one ...
"FDA Approves First Systemic Treatment for Alopecia Areata". U.S. Food and Drug Administration (FDA) (Press release). 13 June ... Tofacitinib for alopecia universalis. Topical tofacitinib and ruxolitinib for alopecia. Kontzias A, Kotlyar A, Laurence A, ... "JAK Inhibitors Showing Promise for Many Skin Problems - Conditions ranging from alopecia to vitiligo". 6 July 2017. Archived ...
Chacín cannot grow hair because of alopecia areata. Gustavo Chacín and MLB pitcher Jhoulys Chacín are second cousins (once ...
It has also been used successfully in the treatment of alopecia areata. Hypersensitivity, use on face, hypercalcaemia, or ... August 2012). "Successful treatment of alopecia areata with topical calcipotriol". Annals of Dermatology. 24 (3): 341-344. doi: ...
"Re-growing hair: New trials for alopecia areata treatment are a success - Technology Org". 29 March 2022. Archived from the ... In June 2022, the FDA authorized baricitinib for the treatment of severe alopecia areata. During pregnancy, the use of ... In March 2020, the US FDA granted breakthrough therapy designation to baricitinib for the treatment of alopecia areata and ... "FDA Approves First Systemic Treatment for Alopecia Areata". U.S. Food and Drug Administration (FDA) (Press release). 13 June ...
Happle R, Van Der Steen P, Perret C (1991). "The Renbök phenomenon: An inverse Köebner reaction observed in alopecia areata". ... Ito, T; Hashizume, H; Takigawa, M (2010). "Contact immunotherapy-induced Renbök phenomenon in a patient with alopecia areata ... Ramot, Y.; Ovcharenko, Y.; Serbina, I.; Zlotogorski, A. (2013). "Renbök phenomenon in an alopecia areata patient with psoriasis ... "Renbök Phenomenon and Contact Sensitization in a Patient with Alopecia Universalis". Archives of Dermatology. 146 (4): 422-425 ...
Khan, Pooya; Beigi, Mohammad (2018), "Diffuse Alopecia Areata", Alopecia Areata, Springer International Publishing, pp. 9-11, ... "Mosaic Hair Regrowth Pattern of Ophiasis and Androgenic Alopecia in a Patient With Alopecia Areata Totalis". Medscape. ( ... Ophiasis is a form of alopecia areata characterized by the loss of hair in the shape of a wave at the circumference of the head ... "eMedicine - Alopecia Areata : Article by Chantal Bolduc, MD, FRCPC". Retrieved 2007-12-03. Muñoz-Pèrez MA, Camacho FM (1999). " ...
Kiełbasińska suffers from alopecia areata, an auto-immune disease. 1Time from the heats; Kiełbasińska was replaced in the final ...
People suffering from alopecia areata have been found to have a different amount of E. eligens from the average person. "BacMap ... "Microbiome: Gut dysbiosis linked to development of alopecia areata". www.mdedge.com. Retrieved 22 May 2023. v t e (Articles ...
Alopecia areata patients can also develop loose anagen syndrome. Loose anagen syndrome usually does not need treatment as this ... Patients with loose anagen syndrome may experience the thinning of their hair which is also a factor of alopecia areata. In ... alopecia areata, telogen effluvium, trichotillomania and toxic ingestion. Similar symptoms and signs appear in these conditions ... A biopsy will display non-inflammatory, non-scarring alopecia. The texture of the hair varies with some reports stating that ...
Alopecia areata List of cutaneous conditions Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2- ... Alopecia neoplastica may present as a scarring alopecia, appearing anywhere on the scalp, and it has been described with ...

No FAQ available that match "alopecia areata"

No images available that match "alopecia areata"